Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States
Background & Aims
In the last decade, significant progress has been made in the treatment of liver disease associated with chronic hepatitis, especially in patients infected with the hepatitis B virus (HBV). To investigate whether the population-wide application of antiviral therapies has impacted liver transplant waiting list registration, we analyzed longitudinal trends in waiting list registration for patients with hepatitis B and C and those with nonviral liver disease.
Methods
This study represented a retrospective analysis of registry data containing all US liver transplant centers. All adult, primary liver transplantation candidates registered to the Organ Procurement and Transplantation Network between 1985 and 2006 were included in the analysis. Standardized incidence rates were calculated for waiting list registration for liver transplantation by underlying disease (HBV and HCV infection and other) and by indication for transplantation (fulminant liver disease, hepatocellular carcinoma [HCC], and end-stage liver disease [ESLD]).
Results
Of 113,927 unique waiting list registrants, 4793 (4.2%) had HBV, and 40,923 (35.9%) had HCV infections; the remaining 68,211 (59.9%) had neither. The incidence of waiting list registration for ESLD and fulminant liver disease decreased, whereas that for HCC increased. The decrease in ESLD registration was most pronounced, and the increase in HCC was least dramatic among registrants with hepatitis B. The decrease in registration for ESLD secondary to HCV infection was also significantly larger than that for ESLD patients with nonviral etiologies.
Conclusions
The pattern of liver transplantation waiting list registration among patients with hepatitis B suggests that the widespread application of oral antiviral therapy for HBV contributed to the decreased incidence of decompensated liver disease.
Abbreviations used in this paper: FLD, fulminant liver disease, HBV, hepatitis B virus, HCC, hepatocellular carcinoma, HCV, hepatitis C virus, LTx, liver transplantation, OPTN, Organ Procurement and Transplantation Network
To access this article, please choose from the options below
Conflicts of interest The authors disclose the following: W. Ray Kim received a grant from the Gilead Sciences, Inc, to conduct this study. He has served as a consultant for Roche, Bristol–Myers–Squibb, Idenix, Schering-Plough, and Gilead Sciences. Norah Terrault has received grants from Gilead Sciences, Cangene, NABI, and Roche and consulted Bristol-Myers-Squibb. Andrew Hindman was a former employee of Gilead Sciences, Inc, and Carol Brosgart was a former employee of Gilead Sciences. Terry Therneau, Rachel Pedersen, and Erick Edwards disclose no conflicts.
Funding Supported by grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK-34238 and DK-61617), and Gilead Sciences, Inc, provided unrestricted grant in partial support of the work; however, the content of the work including data analysis and interpretation was solely that of the authors.
PII: S0016-5085(09)01246-3
doi:10.1053/j.gastro.2009.07.047
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.

